Wellstein A, Pitschner H F
Zentrum der Pharmakologie, Klinikum der J.W. Goethe-Universität, Frankfurt, Federal Republic of Germany.
Naunyn Schmiedebergs Arch Pharmacol. 1988 Jul;338(1):19-27. doi: 10.1007/BF00168807.
In the present study we set out to explain the complex atropine dose-response curves in man in relation to M-cholinoceptor subtype occupancy. In healthy volunteers the effects of atropine on heart rate and salivary flow were quantified. M-cholinoceptor subtype occupancy by antagonist present in plasma samples was detected in an in vitro radioreceptor assay. Atropine effects were studied without and after propranolol (240 mg oral dose) and without and after pirenzepine (1.1 mg i.v.) to differentiate beta-adrenoceptor and M-cholinoceptor subtype mediated effects. 1. In receptor binding studies, M-cholinoceptors in bovine cerebral cortex membranes were labelled with 3H-pirenzepine (pKd = 8.05), M-cholinoceptors in rat salivary gland membranes with 3H-N-methylscopolamine (pKd = 9.02). Atropine competed for binding of these ligands with a small (2.1-fold) preferential selectivity via the cerebral in comparison to the glandular receptors (pKi = 9.18 versus 8.86). Pirenzepine showed a marked selectivity (40-fold) in this respect with pKi-values of 8.05 (M1: cerebral cortex) and 6.45 (M2: salivary glands). 2. At heart rate and at salivary flow, bivalent dose-response curves of atropine were observed with opposite effect vectors. The typical antagonist effects at M-cholinoceptors (i.e. an increase of heart rate and an inhibition of salivary flow) were observed at doses greater than 1 microgram/kg, whereas "paradoxical" cholinomimetic effects of atropine became apparent at lower doses. From a superposition of two isotherms with opposite effect vectors ED50-values were calculated, which were in the range of half-maximal M-cholinoceptor occupancy in the in vitro radioreceptor assay of plasma samples.(ABSTRACT TRUNCATED AT 250 WORDS)
在本研究中,我们着手解释人体中复杂的阿托品剂量 - 反应曲线与M胆碱受体亚型占有率的关系。在健康志愿者中,对阿托品对心率和唾液分泌的影响进行了量化。通过体外放射受体测定法检测血浆样本中拮抗剂对M胆碱受体亚型的占有率。在未使用普萘洛尔(口服剂量240mg)和使用普萘洛尔后,以及未使用哌仑西平(静脉注射1.1mg)和使用哌仑西平后,研究了阿托品的作用,以区分β肾上腺素能受体和M胆碱受体亚型介导的作用。1. 在受体结合研究中,用3H - 哌仑西平(pKd = 8.05)标记牛大脑皮质膜中的M胆碱受体,用3H - N - 甲基东莨菪碱(pKd = 9.02)标记大鼠唾液腺膜中的M胆碱受体。与腺体受体相比,阿托品通过大脑受体对这些配体结合的竞争具有较小的(2.1倍)优先选择性(pKi = 9.18对8.86)。在这方面,哌仑西平表现出明显的选择性(40倍),其pKi值分别为8.05(M1:大脑皮质)和6.45(M2:唾液腺)。2. 在心率和唾液分泌方面,观察到阿托品的二价剂量 - 反应曲线,其效应向量相反。在剂量大于1μg/kg时,观察到M胆碱受体的典型拮抗剂作用(即心率增加和唾液分泌抑制),而阿托品的“矛盾”拟胆碱作用在较低剂量时变得明显。通过叠加两个具有相反效应向量的等温线计算出ED50值,其范围与血浆样本体外放射受体测定中M胆碱受体占有率的半数最大值范围一致。(摘要截断于250字)